Table 4.

Prognostic factors for survivals in 52 patients treated with CLAM

Parameter	No.	Overall survival			Relapse‐free survival			Event‐free survival
		2‐y (%)	HR (95% CI)	P value	2‐y (%)	HR (95% CI)	P value	2‐y (%)	HR (95% CI)	P value
Gender
Male	26	64.5	0.83 (0.32‐2.17)	.71	43.8	0.80 (0.34‐1.91)	.62	38.3	0.78 (0.36‐1.71)	.54
Female	26	61.8	1.20 (0.46‐3.14)		39.9	1.25 (0.53‐2.97)		34.9	1.28 (0.59‐2.79)
Age
18‐45	24	56.0	1.43 (0.55‐3.72)	.46	25.6	1.42 (0.60‐3.34)	.43	17.8	1.74 (0.80‐3.80)	.17
46‐65	28	66.6	0.70 (0.27‐1.81)		51.3	0.71 (0.30‐1.67)		51.8	0.58 (0.26‐1.26)
Status
Relapse	31	62.3	1.28 (0.48‐3.41)	.62	51.7	0.68 (0.29‐1.62)	.39	48.3	0.71 (0.33‐1.53)	.38
Refractory	21	64.4	0.78 (0.29‐2.07)		28.7	1.47 (0.62‐3.46)		23.7	1.42 (0.65‐3.08)
Response
CR	36	84.3	0.11 (0.03‐0.40)	.005	48.5	0.28 (0.11‐0.72)	.008	48.5	0.24 (0.08‐0.71)	.01
CRi	11	39.8	4.81 (1.60‐14.42)		18.2	3.57 (1.40‐9.14)		18.2	3.95 (1.54‐10.13)
NR	5	0	9.32 (2.51‐34.55)		—	—		0	4.18 (1.42‐12.30)
Allogeneic HSCT
Performeda	22	90.0	0.05 (0.007‐0.42)	.005	76.4	0.13 (0.04‐0.40)	<.001	76.4	0.15 (0.05‐0.39)	<.001
Not performed	30	37.3	18.35 (2.40‐140.37)		19.2	7.59 (2.50‐23.04)		14.3	6.90 (2.55‐18.67)

Abbreviations: AML, acute myeloid leukemia; Ara‐C, mitoxantrone; CI, confidence interval; CLAM, clofarabine, cytarabine, and mitoxantrone; CR, complete remission; Cri, complete remission with incomplete hematological recovery; EFS, event‐free survival; HSCT, hematopoietic stem cell transplantation; HR, hazard ratio for event; NR, nonremission; OS, overall survival; R1, first relapse; RFS, relapse‐free survival.

^a2 patients who did not undergo HSCT initially, but underwent HSCT following response to salvage treatment, belonged to the non‐HSCT group.